EFTR (EFTR) Stock Price & Analysis
EFTR (EFTR) rose 0.00% to USD 0 as of June 10, 2026 at 03:28 UTC, according to Nexqual real-time market data.
EFTR last closed at USD 0; the session ranged USD 0–0 on volume of 331 shares. Market capitalization is $940, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 10, 2026 at 03:28 UTC.
Key Statistics (as of June 10, 2026 at 03:28 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 331 shares |
| Market Cap | $940 |
| Exchange | PNK |
Technical Analysis (EFTR)
Nexqual's technical model rates EFTR "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:28 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.02 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (EFTR)
Wall Street analysts rate EFTR "None", per Nexqual as of June 10, 2026 at 03:28 UTC.
| Consensus Rating | None |
|---|
Earnings (EFTR)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-03-31 | USD -2.16 vs est -2.17 ▲ beat |
| 2023-12-31 | USD -3.42 vs est -2.73 ▼ miss |
| 2023-09-30 | USD -3.25 vs est -3.08 ▼ miss |
| 2023-06-30 | USD -4.25 vs est -4.94 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financials & Fundamentals (EFTR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 2,448.37 |
| Current Ratio | 1.03 |
| Total Cash | $25.38M |
| Total Debt | $20.25M |
| Free Cash Flow | $-17.67M |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financial Health Score (EFTR)
Nexqual rates EFTR's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:28 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Critical — $25M cash vs $20M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$29M |
| Efficiency | Mixed — No data |
Ownership (EFTR)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 4.70M |
| Float | 4.67M |
| Short % of Float | +1.97% |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BTTX | Better Therapeutics, Inc. | USD 0 | ▲ 0% |
| INDP | Indaptus Therapeutics, Inc. | USD 2.03 | ▼ 44.67% |
| JSPR | Jasper Therapeutics, Inc. | USD 0.47 | ▼ 5.48% |
| VRPX | Virpax Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| ABVC | ABVC Biopharma, Inc. | USD 1.32 | ▼ 0.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:28 UTC. This page is informational and not investment advice.